NEXT Financial Group Inc trimmed its position in Eli Lilly and Co (NYSE:LLY) by 38.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,029 shares of the company’s stock after selling 4,961 shares during the period. NEXT Financial Group Inc’s holdings in Eli Lilly and were worth $678,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in LLY. E&G Advisors LP purchased a new position in shares of Eli Lilly and during the 4th quarter valued at about $372,000. Bank of Montreal Can lifted its position in shares of Eli Lilly and by 85.4% during the 4th quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock valued at $391,156,000 after buying an additional 2,133,606 shares in the last quarter. Solaris Asset Management LLC lifted its position in shares of Eli Lilly and by 28.4% during the 4th quarter. Solaris Asset Management LLC now owns 4,525 shares of the company’s stock valued at $382,000 after buying an additional 1,000 shares in the last quarter. Starfire Investment Advisers Inc. purchased a new position in shares of Eli Lilly and during the 4th quarter valued at about $483,000. Finally, Hexavest Inc. lifted its position in shares of Eli Lilly and by 1.7% during the 4th quarter. Hexavest Inc. now owns 1,360,139 shares of the company’s stock valued at $114,877,000 after buying an additional 22,492 shares in the last quarter. 76.35% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Co (LLY) traded down $1.69 during midday trading on Tuesday, reaching $85.29. The company had a trading volume of 4,772,240 shares, compared to its average volume of 2,944,430. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a one year low of $74.00 and a one year high of $89.09. The stock has a market cap of $93,910.00, a PE ratio of 40.61, a PEG ratio of 1.63 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the previous year, the firm earned $0.88 EPS. The firm’s revenue was up 9.0% compared to the same quarter last year. sell-side analysts predict that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 2.64%. Eli Lilly and’s payout ratio is currently 99.05%.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 12,500 shares of Eli Lilly and stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $86.46, for a total value of $1,080,750.00. Following the sale, the senior vice president now owns 124,522 shares of the company’s stock, valued at approximately $10,766,172.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now directly owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 251,088 shares of company stock worth $22,041,236. 0.20% of the stock is owned by insiders.
LLY has been the topic of a number of analyst reports. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, December 12th. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and lifted their price objective for the company from $85.52 to $115.00 in a research report on Friday, January 5th. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Thursday, October 26th. Finally, Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $92.75.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.truebluetribune.com/2018/01/16/next-financial-group-inc-reduces-holdings-in-eli-lilly-and-co-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.